 REDWOOD CITY, Calif., May 18, 2021 GLOBE NEWSWIRE -- Revolution Medicines, Inc. Nasdaq: RVMD, a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming Cowen 2nd Annual Virtual Oncology Innovation Summit. Steve Kelsey, M.D., president, research and development, will be the featured speaker in a fireside chat at the event. 